Tumorigenicity of mouse BALB/c 3T3 fibroblast cells which express Epstein-Barr virus-encoded LMP1 and show normal growth phenotypes in vitro is correlated with loss of transforming growth factor-β1-mediated growth inhibition

[1]  J. Salisbury,et al.  Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells , 1997, Oncogene.

[2]  J. Chen,et al.  Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. , 1996, The Journal of general virology.

[3]  S. Sharma,et al.  Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. , 1995, Journal of immunology.

[4]  W. Miller,et al.  The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor , 1995, Journal of virology.

[5]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[6]  C. Ware,et al.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family , 1995, Cell.

[7]  M. Rowe,et al.  Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers , 1994, Journal of virology.

[8]  Tony Hunter,et al.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.

[9]  H. Moses,et al.  Mechanisms of transforming growth factor-beta 1-induced cell cycle arrest. , 1994, Invasion & metastasis.

[10]  James M. Roberts,et al.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.

[11]  G. Evan,et al.  The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. , 1993, The EMBO journal.

[12]  R. Eisenman,et al.  A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. , 1993, Genes & development.

[13]  H. Satoh,et al.  Engraftment of human non‐hodgkin lymphomas in mice with severe combined immunodeficiency , 1993, Cancer.

[14]  S. Korsmeyer,et al.  Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2 , 1993, Journal of virology.

[15]  M. Sakaguchi,et al.  Marek's disease virus protein kinase gene identified within the short unique region of the viral genome is not essential for viral replication in cell culture and vaccine-induced immunity in chickens. , 1993, Virology.

[16]  James M. Roberts,et al.  Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. , 1993, Science.

[17]  D. Thorley-Lawson,et al.  All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts , 1993, Journal of virology.

[18]  R. Eisenman,et al.  Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity , 1993, Cell.

[19]  R. Brent,et al.  Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites , 1993, Cell.

[20]  Carol D. Laherty,et al.  The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. , 1992, The Journal of biological chemistry.

[21]  E. Kieff,et al.  Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells , 1992, Journal of virology.

[22]  M. Welsh,et al.  Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells , 1991, Molecular and cellular biology.

[23]  E. Kieff,et al.  Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death , 1991, Cell.

[24]  C. Missero,et al.  Induction of transforming growth factor beta 1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  E. Kieff,et al.  Early events in Epstein-Barr virus infection of human B lymphocytes. , 1991, Virology.

[26]  R. Eisenman,et al.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.

[27]  J. Massagué,et al.  Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation , 1990, Cell.

[28]  J. Lacy,et al.  Post‐transcriptional mechanisms of deregulation of MYC following conversion of a human B cell line by Epstein‐Barr virus. , 1989, The EMBO journal.

[29]  E. Kieff,et al.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity , 1988, Journal of virology.

[30]  V. Baichwal,et al.  Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. , 1988, Oncogene.

[31]  E. Kieff,et al.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.

[32]  J. Rhim,et al.  Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene , 1983, Nature.